Skip to Main Content




The β-lactam antibiotics are useful and frequently prescribed antimicrobial agents that share a common structure and mechanism of action: inhibition of synthesis of the bacterial peptidoglycan cell wall. The group includes penicillins, cephalosporins, and carbapenems.


The penicillins consist of penicillins G and V, which are highly active against susceptible gram-positive cocci; penicillinase-resistant penicillins such as nafcillin, which are active against penicillinase-producing Staphylococcus aureus; ampicillin and other agents with an improved gram-negative spectrum, especially when combined with a β-lactamase inhibitor; and extended-spectrum penicillins with activity against Pseudomonas aeruginosa, such as piperacillin.


The β-lactams also include the cephalosporin antibiotics, which are classified by generation: First-generation agents have excellent gram-positive and modest gram-negative activity; second-generation agents have somewhat better activity against gram-negative organisms and include some agents with antianaerobe activity; third-generation agents have activity against gram-positive organisms and much more activity against the Enterobacteriaceae, with a subset active against P. aeruginosa; and fourth-generation agents encompass the antimicrobial spectrum of all the third-generation agents and have increased stability to hydrolysis by inducible chromosomal β-lactamases.


Carbapenems, including imipenem, doripenem, ertapenem and meropenem, have the broadest antimicrobial spectrum of any antibiotic, whereas the monobactam aztreonam has a gram-negative spectrum resembling that of the aminoglycosides.


β-Lactamase inhibitors such as clavulanate are used to extend the spectrum of penicillins against β-lactamase-producing organisms. Bacterial resistance against the β-lactam antibiotics continues to increase at a dramatic rate. Mechanisms of resistance include not only production of β-lactamases that in some cases destroy all β-lactam antibiotics, but also alterations in or acquisition of novel penicillin-binding proteins PBPs and decreased entry and/or active efflux of the antibiotic. It is not an exaggeration to state that we are re-entering the pre-antibiotic era, with many nosocomially acquired gram-negative bacterial infections resistant to all available antibiotics.




Despite the existence of microbial resistance, the penicillins constitute one of the most important groups of antibiotics. Many of these have unique advantages such that members of this group of antibiotics are currently the drugs of choice for a large number of infectious diseases.


History. The history of the brilliant research that led to the discovery and development of penicillin is well chronicled. In 1928, while studying Staphylococcus variants in the laboratory at St. Mary's Hospital in London, Alexander Fleming observed that a mold contaminating one of his cultures caused the bacteria in its vicinity to undergo lysis. Broth in which the fungus was grown was markedly inhibitory for many microorganisms. Because the mold belonged to the genus Penicillium, Fleming named the antibacterial substance penicillin.

A decade later, penicillin was developed as a systemic therapeutic agent by the concerted research of a group of investigators at Oxford University headed by Florey, Chain, and Abraham. By May 1940, a crude preparation was found to produce dramatic therapeutic effects when ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessAnesthesiology

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.